Atlas Trials

Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab

Clinical trial NCT03157830 · COMPLETED

Trial details

NCT number
NCT03157830
Sponsor
Providence Health & Services
Status
COMPLETED
Study type
OBSERVATIONAL
Relapsing Remitting Multiple Sclerosis
Start date
2017-06-01
Primary completion
2022-01-28
Enrollment
43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.